Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2252W HIGH $5.00
Volume
155.11 K
Value Traded
355.30 K
Short % Float
0.35%
Days to Cover
1.1
+13.45%Week
-0.51%1 Month
-5.83%3 Month
+2.11%6 Month
+18.71%5 Year
+18.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
49.28 M
EPS (TTM)
-0.83
P/E Ratio
-
Ent. Value
26.25 M
Total Shares
25.40 M
Float Shares
12.40 M
Insiders
51.20%
Institutions
5.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SER Catalyst Timeline
Dated clinical, regulatory and corporate events for Serina Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Serina Therapeutics, Inc.
232Total events
6Upcoming
48Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Serina to present at H.C. Wainwright 28th Annual Global Investment Conference
◆Oral PresentationPresentation
Management to participate in BTIG Virtual Biotechnology Conference
▲Enrollment CompleteSER-252Trial
Completion of sentinel dosing in Cohort 1
advanced Parkinson's diseasesource ↗
▲Enrollment UpdateSER-252Trial
Dosing of additional patients in Cohort 1 underway
advanced Parkinson's diseasesource ↗
◆DSMB ReviewSER-252Trial
Blinded evaluation of safety and tolerability by Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2
advanced Parkinson's diseasesource ↗
▲Enrollment CompleteSER-252Trial
Completed enrollment and dosing of all eight patients in Cohort 1 of SER-252 Phase 1b registrational study
Parkinson's diseasesource ↗
◆Enrollment MilestoneSER-252Trial
Blinded review of safety and tolerability data from Cohort 1 expected to support advancement to Cohort 2
advanced Parkinson's diseasesource ↗
●Management ChangeCorporate
Appointed Farrell Simon, Pharm.D., to Board of Directors and Audit and Compensation Committees
▲Partnership / LicenseSER-252Corporate
Entered into development partnership with Gannet BioChem for SER-252 process development and manufacturing
▼Equity OfferingCorporate
Second tranche of up to $15 million private placement expected to close
▲First Patient DosedSER-252Trial
Dosing of Phase 1b first patient in Cohort 2 on or after April 30, 2026
Parkinson's diseasesource ↗
▲First Patient DosedSER-252Trial
First patient dosed in SER-252 Phase 1b registrational study
advanced Parkinson's diseasesource ↗
●Dose Finding UpdateSER-252Trial
Dosing of Phase 1b last patient in Cohort 1 on or after March 15, 2026
Parkinson's diseasesource ↗
▲First Patient DosedSER-252Trial
First patient dosed in Phase 1b registrational trial of SER-252
advanced Parkinson's diseasesource ↗
◆Oral PresentationPresentation
Serina CEO presents at Tribe Public Webinar: Navigating the New FDA Era
▲First Patient DosedSER-252Trial
First patient dosed in SER-252 Phase 1b registrational trial
Parkinson's diseasesource ↗
▲Trial InitiationSER-252Trial
Phase 1b clinical site start-up and regulatory activities in Australia underway
advanced Parkinson's diseasesource ↗
◆First Patient DosedSER-252Trial
First-patient-in targeted for Q1 2026
advanced Parkinson's diseasesource ↗
▲Clinical Hold LiftedSER-252IND
Clinical hold resolution expected before FPI
advanced Parkinson's diseasesource ↗
●Enrollment MilestoneSER-252Trial
Enrollment initiation in US expected in Q1 2026
Parkinson's diseasesource ↗
●Enrollment MilestoneSER-252Trial
Enrollment of Phase 1b first patient on or after December 15, 2025
Parkinson's diseasesource ↗
◆IND Safety ReportSER-252IND
Serina submitted complete response to FDA clinical hold letter
advanced Parkinson's diseasesource ↗
◆FDA Feedback ReceivedSER-252FDA Meeting
FDA to provide formal clinical-hold letter within 30 days
advanced Parkinson's diseasesource ↗
▼Clinical Hold PlacedSER-252IND
FDA placed clinical hold on SER-252 IND
advanced Parkinson's diseasesource ↗
▼Clinical Hold PlacedSER-252IND
FDA placed clinical hold on IND for SER-252 due to request for additional information on excipient
advanced Parkinson's diseasesource ↗
●IND SubmissionSER-252IND
IND submission for SER-252 (implied by clinical hold)
advanced Parkinson's diseasesource ↗
▲Equity OfferingCorporate
First $5 million tranche drawn under up to $20 million financing agreement
▲Other Regulator MilestoneSER-252Ex-US Regulatory
First HREC approval received in Australia for SER-252
advanced Parkinson's diseasesource ↗
●Trial InitiationSER-252Trial
Global trial initiation expected in Q4 2025
advanced Parkinson's diseasesource ↗
▲First Patient DosedSER-252Trial
First patient dosed in Phase 1b clinical trial expected in Q4 2025
Advanced Parkinson's Diseasesource ↗
▲IND ClearanceSER-252IND
US IND clearance anticipated before Q1 2026 enrollment
Parkinson's diseasesource ↗
▼Equity OfferingCorporate
Up to $20 million convertible note financing led by Board Director Greg Bailey
▼Equity OfferingCorporate
Convertible note and warrant financing agreement for up to $20 million; first $5 million tranche drawn in September 2025
▲Type B MeetingSER-252FDA Meeting
Type B meeting with FDA in August 2025; FDA written feedback supported 505(b)(2) NDA pathway
advanced Parkinson's diseasesource ↗
▲Development Candidate NominationSER-270Preclinical
Serina advances POZ-VMAT2i (SER-270) into development for tardive dyskinesia
tardive dyskinesiasource ↗
Past FDA Catalysts and PDUFA Decisions
How SER actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 93%
Micro Cap(rank 611 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SER-252 Small moleculeNCT07422675 | PARKINSON DISEASE (Disorder) | Phase 1 | RECRUITING | 40 | Jan 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every SER program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brannan Stephen K.Director | Buy | 1,000 1,000 held | $2.03 | 07/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SER
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SER for Q2 2026. | ||||
SER Institutional Ownership Trends
SER Short Interest
Shares sold short, counted twice a month.
0.35%
Short % of Float
of tradable shares sold short
43.9K
Shares Sold Short
-22.5% vs prior count
1.1 Low
Days to Cover
trading days of normal volume to buy every short share back
38.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SER ranks across every disease it competes in
Competitive Position is a premium feature
See how SER ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSER News
-SER
Oct 19, 2026Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System
Enable Injections has received regulatory approval in Japan for its enFuse On-Body Delivery System, specifically for the CirCLIQ Injector used to administer Sarclisa for multiple myeloma. This marks the first approval of an anticancer treatment via an on-body injector in Japan. The approval is based on positive results from the IRAKLIA phase 3 study, demonstrating the efficacy of the subcutaneous formulation.
Read more →-SER
Sep 23, 2026Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
Serina Therapeutics is hosting a webinar featuring CEO Steven Ledger to discuss SER-252's clinical progress in treating advanced Parkinson's disease. The event, scheduled for September 24, 2026, aims to engage participants by allowing them to submit questions. This initiative highlights Serina's commitment to addressing the challenges faced by Parkinson's patients.
Read more →-SER
Sep 10, 2026▼ -11.2%on this news
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Serina Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026. CEO Steve Ledger will discuss the company's proprietary POZ Platform™ drug optimization technology, which targets neurological diseases. The presentation will be available for on-demand viewing starting September 14, 2026.
Read more →-SER
Sep 9, 2026Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
Serina Therapeutics announced that its SER-252 study for advanced Parkinson's disease has progressed to Cohort 2 following positive recommendations from the Safety Monitoring Committee. Cohort 1 demonstrated a favorable safety profile and sustained motor function improvements in patients. The company plans to report topline data in the first half of 2027.
Read more →-SER
Aug 13, 2026Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Serina Therapeutics reported its second quarter 2026 financial results, highlighting the completion of enrollment and dosing in Cohort 1 of the SER-252 Phase 1b study. The company anticipates top-line data in the first half of 2027. Additionally, Serina appointed Farrell Simon to its Board of Directors to enhance its strategic capabilities. However, the company reported an increased net loss and higher operating expenses compared to the previous year.
Read more →-SER
Jul 24, 2026Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Serina Therapeutics will participate in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. The company aims to showcase its proprietary POZ Platform™, which enhances drug delivery and addresses pharmacokinetic limitations. Management will hold one-on-one investor meetings, emphasizing their commitment to advancing their innovative drug candidates.
Read more →-SER
Jul 23, 2026Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Serina Therapeutics has successfully completed enrollment and dosing in Cohort 1 of its Phase 1b trial for SER-252, a treatment for advanced Parkinson's disease. This milestone was achieved ahead of the previously expected timeline. An independent Safety Monitoring Committee will review the safety and tolerability data before the next dose-escalation decision is made. The trial aims to evaluate the safety and pharmacokinetics of SER-252 compared to placebo.
Read more →-SER
Jul 22, 2026Serina Therapeutics Appoints Farrell Simon to its Board of Directors
Serina Therapeutics has appointed Farrell Simon, Pharm. D., to its Board of Directors. Dr. Simon brings extensive experience from Trevi Therapeutics and Pfizer, which will aid Serina in advancing its SER-252 program. The company aims to leverage its POZ Platform™ technology to enhance drug delivery for neurological diseases.
Read more →-SER
Jul 9, 2026Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Serina Therapeutics has completed sentinel dosing in Cohort 1 of its Phase 1b trial for SER-252, aimed at treating advanced Parkinson's disease. The independent Safety Monitoring Committee has recommended continuing dosing based on initial safety observations. The company anticipates completing enrollment and dosing ahead of the previously set timeline of Q3 2026.
Read more →-SER
May 22, 2026Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi
Enable Injections announced the CE Certification of its enFuse® On-Body Delivery System for use with Aspaveli®, enhancing patient access to treatment for conditions like PNH and C3G. This certification allows for subcutaneous administration, improving convenience and safety. The enFuse system is set to be distributed by Sobi across the EU, marking a significant milestone in their partnership.
Read more →-SER
May 14, 2026▲ +10.3%on this news
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Serina Therapeutics has reported its financial results for Q1 2026 and provided updates on its business operations. The company has initiated a Phase 1b registrational clinical study for SER-252, targeting advanced Parkinson's disease, with data from the study expected in early 2027. Additionally, Serina has successfully closed a $21.2 million private placement to support its ongoing development. However, the company also reported an increase in net loss and operating expenses compared to the previous year.
Read more →-SER
Apr 3, 2026Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
Serina Therapeutics has received acceptance from NYSE American for its compliance plan to meet listing standards. The company aims to regain compliance by July 2027 while continuing its SER-252 clinical program. However, it faces challenges due to previous financial losses and low stockholders' equity.
Read more →-SER
Mar 26, 2026▼ -13.9%on this news· ran to -36% by day 3
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Serina Therapeutics reported its financial results for 2025, highlighting significant advancements including FDA clearance for SER-252 and the initiation of its Phase 1b trial for Parkinson's disease. The company secured up to $30 million in financing, enhancing its clinical and financial position. However, it also reported an increased net loss and rising operating expenses.
Read more →-SER
Mar 24, 2026▼ -22.9%on this newsshared move
Serina Therapeutics to Present at the 38th Annual Roth Conference
Serina Therapeutics will present at the 38th Annual Roth Conference on March 24, 2026. CEO Steve Ledger will discuss the company's proprietary POZ Platform™ technology and its applications in treating neurological diseases. The presentation will be available via live webcast and archived for 90 days. The POZ technology aims to enhance drug delivery and efficacy.
Read more →-SER
Mar 20, 2026Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease
Serina Therapeutics has announced a private placement that will raise up to $30 million to support the registrational trial of its drug SER-252 for advanced Parkinson's disease. The funding includes an initial tranche of $15 million expected to close on March 20, 2026, and a second tranche of the same amount anticipated shortly after. The financing structure is designed to align capital deployment with upcoming clinical milestones, including the ongoing registrational study aimed at providing a new treatment option for patients inadequately served by current therapies. Serina's approach is bolstered by a favorable regulatory pathway confirmed by recent FDA feedback.
Read more →-SER
Feb 25, 2026▲ +6%on this news
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Serina Therapeutics has initiated dosing in its Phase 1b registrational trial for SER-252, targeting advanced Parkinson's disease. The trial aims to assess the safety and efficacy of SER-252, which utilizes the company's proprietary POZ Platform™. With FDA alignment on its regulatory pathway, Serina is positioned to generate critical clinical data.
Read more →-SER
Feb 3, 2026Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
Serina Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Steven Ledger, will present at a webinar titled 'Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences' on February 4, 2026. The event will allow participants to ask questions directly to the CEO. Registration is available through Tribe Public's website.
Read more →-SER
Jan 29, 2026▲ +30.1%on this newsshared move
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
Serina Therapeutics has received FDA clearance for its IND application for SER-252, an investigational therapy aimed at treating advanced Parkinson's disease. This clearance enables the company to start regulatory activities and initiate a Phase 1b clinical study. The CEO emphasized the importance of this milestone and the potential of SER-252 to meet significant medical needs.
Read more →-SER
Dec 11, 2025Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
Serina Therapeutics has submitted a complete response to the FDA regarding the clinical hold on its SER-252 program for advanced Parkinson's disease. The FDA's hold was due to requests for additional information on a formulation excipient. The company is actively preparing for a Phase 1b study, aiming for the first patient to be enrolled in early 2026, pending FDA feedback.
Read more →-SER
Dec 10, 2025Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program - Company addresses FDA requests regarding formulation excipient
Serina Therapeutics has submitted a complete response to the FDA's clinical hold letter regarding its lead program, SER-252, for advanced Parkinson's disease. The move addresses the FDA's requests related to the formulation excipient trehalose and includes a detailed data package. The company continues its global site start-up activities, aiming for first patient enrollment in Q1 2026, pending FDA feedback. CEO Steve Ledger expressed optimism around their submission and the potential progression of the trial.
Read more →About Serina Therapeutics, Inc.
Headquarters601 GENOME WAY, HUNTSVILLE, AL, 35806
Founded2018
BIOPHARMAWATCH ELITE PLUS
Trade the next SER catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime